Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation

被引:55
|
作者
Tanabe, K
Tokumoto, T
Ishikawa, N
Koyama, I
Takahashi, K
Fuchinoue, S
Kawai, T
Koga, S
Yagisawa, T
Toma, H
Ota, K
Nakajima, H
机构
[1] Tokyo Womens Med Coll, Kidney Ctr, Dept Urol & Surg 3, Tokyo 162, Japan
[2] Niigata Univ, Dept Urol, Niigata, Japan
[3] Mitsubishi Kagaku Bioclin Labs Inc, Dept Infect Dis, Tokyo, Japan
关键词
D O I
10.1097/00007890-199712270-00016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Early diagnosis of cytomegalovirus (CMV) infection, which is an important cause of morbidity and mortality in renal transplant recipients, remains of great importance, This prospective study was performed in kidney transplant recipients to determine the diagnostic value of the CMV antigenemia assay in comparison with polymerase chain reaction (PCR), serology, and shell vial assay. Methods. Seventy-five consecutive renal transplant recipients were enrolled in this study and monitored by both antigenemia assay and serology. The initial 34 of the 75 patients were subjected to PCR and shell vial assay, Results. Antigenemia, PCR, and shell vial assay became positive before the onset of CMV-related symptoms in 31/34 (89%), 13/16 (81%), and 2/16 (13%), respectively, None of the 34 patients who had symptomatic CMV disease showed a significant increase in IgG or IgM before the onset of symptoms, Antigenemia and PCR assays turned positive, 7 and 11 days (median), respectively, before the onset of clinical symptoms. Serology and shell vial assay became positive 21 and 25 days (median), respectively, after the onset of CMV-related clinical symptoms, To examine the clinical value of these assays, "good correlation" was defined based on the correlation between the clinical course and the results of the assays. Good correlation with the antigenemia assay was observed in 33 (96%) out of 34 renal transplant recipients who recovered from their CMV disease after ganciclovir therapy. Only one of 16 (7%) patients showed good correlation by shell vial assay, whereas PCR and serology did not show a good correlation. Consequently, antigenemia was considered the best way to monitor CMV infections after kidney transplantation. Conclusions. Only the CMV antigenemia assay can be successfully employed after renal transplantation for the early diagnosis and extensive monitoring of active CMV infection.
引用
收藏
页码:1721 / 1725
页数:5
相关论文
共 50 条
  • [21] COMPARISON OF THE CYTOMEGALOVIRUS ANTIGENEMIA (CMV-AG) TEST WITH CONVENTIONAL MODALITIES IN THE DIAGNOSIS AND MONITORING OF CMV AFTER RENAL-TRANSPLANT
    MURRAY, BM
    GRAY, V
    PAWLOWSKI, I
    SCHWEGLER, K
    BRENTJENS, J
    AMSTERDAM, D
    VENUTO, R
    CLINICAL RESEARCH, 1992, 40 (03): : A754 - A754
  • [22] Cytomegalovirus (CMV) Monitoring After Liver Transplantation: Comparison of CMV Pp65 Antigenemia Assay with Real-Time PCR Calibrated to WHO International Standard
    Kamei, Hideya
    Ito, Yoshinori
    Onishi, Yasuharu
    Suzuki, Michio
    Imai, Hisashi
    Kurata, Nobuhiko
    Hori, Tomohide
    Tainaka, Takahisa
    Uchida, Hiroo
    Ogura, Yasuhiro
    ANNALS OF TRANSPLANTATION, 2016, 21
  • [23] Comparison of antigenemia (pp65) assay and polymerase chain reaction in diagnosis of cytomegalovirus infection in renal transplant recipients treated with ATG
    Durlik, M
    Siennicka, J
    Litwinska, B
    Majchrzak, J
    Paczek, L
    Lao, M
    Samsel, R
    Chmura, A
    Kantoch, M
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (06) : 1350 - 1352
  • [24] QUANTITATIVE IMMUNODETECTION OF CYTOMEGALOVIRUS ANTIGENEMIA IN THE CLINICAL-DIAGNOSIS OF CMV INFECTION AFTER HEART-TRANSPLANTATION
    KOSKINEN, P
    NIEMINEN, M
    MATTILA, S
    LAUTENSCHLAGER, I
    TRANSPLANTATION PROCEEDINGS, 1993, 25 (01) : 1426 - 1426
  • [25] POLYMERASE CHAIN-REACTION (PCR) FOR THE PRESYMPTOMATIC DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION FOLLOWING LIVER-TRANSPLANTATION (LT)
    MUTIMER, DJ
    SHAW, JC
    UMANA, JP
    NEUBERGER, JM
    ELIAS, E
    HEPATOLOGY, 1992, 16 (04) : A50 - A50
  • [26] Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation.
    Ohnishi, M
    Kanda, Y
    Saito, T
    Niiya, H
    Nakai, K
    Takeuchi, T
    Tanosaki, R
    Kunitoh, H
    Kobayashi, Y
    Tobinai, K
    Mineishi, S
    Takaue, Y
    BLOOD, 2000, 96 (11) : 342B - 342B
  • [27] Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction
    K Yakushiji
    H Gondo
    K Kamezaki
    K Shigematsu
    S Hayashi
    M Kuroiwa
    S Taniguchi
    Y Ohno
    K Takase
    A Numata
    K Aoki
    K Kato
    K Nagafuji
    K Shimoda
    T Okamura
    N Kinukawa
    N Kasuga
    M Sata
    M Harada
    Bone Marrow Transplantation, 2002, 29 : 599 - 606
  • [28] Indication of ganciclovir treatment during early cytomegalovirus (CMV) viremia in CMV seropositive recipients. A longitudinal study of CMV pp65 antigenemia (Ag) assay.
    Yang, CW
    An, HJ
    Kim, YO
    Shin, YS
    Chang, YS
    Bang, BK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3404 - A3404
  • [29] Optimal indication of gancyclovir treatment during early cytomegalovirus (CMV) viremia in CMV seropositive recipients. A longitudinal study of CMV pp65 antigenemia assay.
    Yang, CW
    Lee, SH
    Yoon, SN
    An, HJ
    Kim, YO
    Shin, YS
    Kim, YS
    Choi, EJ
    Bang, BK
    KIDNEY INTERNATIONAL, 1997, 51 (03) : 961 - 961
  • [30] PROSPECTIVE EVALUATION OF THE POLYMERASE CHAIN-REACTION (PCR) FOR THE DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION FOLLOWING LIVER-TRANSPLANTATION (LT)
    MUTIMER, D
    SHAW, J
    ODONNELL, K
    MCLEISH, P
    BUCHAN, A
    MCMASTER, P
    NEUBERGER, J
    ELIAS, E
    HEPATOLOGY, 1993, 18 (04) : A72 - A72